Make India manufacturing hub: Mansukh Mandaviya urges Pharma industry

Published On 2021-10-28 08:47 GMT | Update On 2021-10-28 08:47 GMT

New Delhi: Union Chemicals and Fertilisers Minister Mansukh Mandaviya on Wednesday urged the pharma industry to make India manufacturing hub as the country is a safe destination for investments.

Addressing the Investor Summit on 'Opportunities & Partnerships in Pharma & Medical Devices', he also spoke about the government's pro-industry reforms and efforts to make India the best investment destination in the world.

"I would like to tell investors what Prime Minister Modi has already said. Please come and manufacture in India, set up industry here. The country provides a safe investment environment as you would find in your own countries," Mandaviya said during an online event.

He noted that the government has been taking constant steps to enhance investments in the country and the global pharma industry should benefit from it.

There were no biases against people coming to invest from outside and everyone was treated equally, he said, outlining the reasons for growth of the industry in the country.

Mandaviya, who is also the Union health minister, said the government is looking to make the country a pharma hub and noted that the government is in the process of setting up three bulk drug parks in the country.

Around Rs 30,000 crore has been lined up as part of the two Production-Linked Incentive (PLI) schemes in the pharma sector, Mandaviya said.

Further, he noted that India is rightly called the pharmacy of the world as it is the largest manufacturer and supplier of generic medicines.

During the COVID period, the country supplied medicines to more than 150 countries, the minister noted.

"It shows that the pharma industry is not just a business in India. It is connected with our sentiments. It is not governed with only profit motive but is guided by the Indian philosophy of Vasudhaiva Kutumbakam," he added.

Further, the minister said the domestic pharma industry has witnessed growth in COVID times and it has been due to the pro-industry policies formed by the government.

He assured investors that they will be treated fairly in India, given its robust regulatory mechanism, independent judiciary and democratic form of government.

Mandaviya stated that under the able leadership of the prime minister. India strives to become the best investment destination in the world for the pharma sector.

He noted that the pharma sector has witnessed a substantial increase in investments.

FDI in the sector increased 98 per cent year on year in 2020 and exports from India grew by 18 per cent in the last financial year.

The Investor Summit was organised by the Department of Pharmaceuticals in partnership with Invest India.

Article Source : PTI

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Ruchika Sharma

Ruchika Sharma joined Medical Dialogue as an Correspondent for the Business Section in 2019. She covers all the updates in the Pharmaceutical field, Policy, Insurance, Business Healthcare, Medical News, Health News, Pharma News, Healthcare and Investment. She has completed her B.Com from Delhi University and then pursued postgraduation in M.Com. She can be contacted at editorial@medicaldialogues.in Contact no. 011-43720751

Comments Policy

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Gilead Sciences gets USFDA nod for new Biktarvy indication for people with HIV who are treatment experienced, restarting antiretroviral treatment

2025-08-02 07:00 GMT

Make India manufacturing hub: Mansukh Mandaviya urges Pharma industry

Similar News

Health Ministry Notifies Cosmetics Rules 2025, Empowers States To Suspend Licences

Biodeal Told To Justify Novel Delivery Claim In NPPA Exemption Plea For Midazolam Nasal Spray

CDSCO Panel Accepts Phase I Trial Data for Intas' Denosumab Biosimilar

Torrent Pharma: USFDA concludes inspection at Vizag facility with zero observations

Gilead Sciences gets USFDA nod for new Biktarvy indication for people with HIV who are treatment experienced, restarting antiretroviral treatment

USFDA issues 4 observations for Jubilant Generics Roorkee facility

Granules India arm gets 1 USFDA observation for Hyderabad facility

CDSCO Panel Clears PURE & CURE's Sickle Cell Trial With Conditions On Sample Size, Sites